Humoral aspects of polymyositis/dermatomyositis

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Evidence of the involvement of systemic autoimmunity has been observed in polymyositis/dermatomyositis (PM/DM). Autoantibodies directed against various cellular constituents have been detected in most patients with PM/DM, and about one-third of patients have autoantibodies (myositis-specific antibodies: MSAs) that are found specifically in myositis patients. These autoantibodies are closely associated with a characteristic clinical subgroup, and therefore help in establishing the correct diagnosis, classifying the myositis patients in a homogeneous subset, and facilitating the clinical and treatment follow-up. Autoantibodies to six of the aminoacyl tRNA synthetases are each associated with a similar syndrome marked by myositis, interstitial lung disease, arthritis, and other features constituting an “antisynthetase syndrome.” Antibodies to other cytoplasmic antigens that are involved in protein synthesis or translation factors are seen in a small proportion of patients. Antisignal recognition particles are associated with severe, refractory myositis that differs significantly from antisynthetase syndrome. Antibodies to the nuclear antigen are specifically seen in patietnts with DM. Several autoantibodies, including anti-U1 RNP, anti-U2 RNP, anti-Ku, and anti-PM-Scl, have been associated with scleroderma–PM overlap. In recent years, these MSAs and their antigens have been characterized using molecular biology approaches. It is not known if the MSAs are involved in tissue injury or the pathogenesis of PM/DM. However, an understanding of the production mechanisms of these autoantibodies can provide insight into the etiology of this disorder.

Original languageEnglish
Pages (from-to)199-206
Number of pages8
JournalModern Rheumatology
Volume10
Issue number4
DOIs
Publication statusPublished - 2000 Jan 12

Fingerprint

Dermatomyositis
Myositis
Autoantibodies
Antibodies
Antigens
Amino Acyl-tRNA Synthetases
Nuclear Antigens
Interstitial Lung Diseases
Autoimmunity
Arthritis
Molecular Biology
Wounds and Injuries
Proteins

Keywords

  • Anti-SRP antibodies
  • Antiaminoacyl-tRNA synthetase
  • Interstitial lung disease
  • Myositis-specific autoantibodies
  • Polymyositis/dermatomyositis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Humoral aspects of polymyositis/dermatomyositis. / Hirakata, Michito.

In: Modern Rheumatology, Vol. 10, No. 4, 12.01.2000, p. 199-206.

Research output: Contribution to journalReview article

@article{1e450281714a4b959fca746fd0be39c5,
title = "Humoral aspects of polymyositis/dermatomyositis",
abstract = "Evidence of the involvement of systemic autoimmunity has been observed in polymyositis/dermatomyositis (PM/DM). Autoantibodies directed against various cellular constituents have been detected in most patients with PM/DM, and about one-third of patients have autoantibodies (myositis-specific antibodies: MSAs) that are found specifically in myositis patients. These autoantibodies are closely associated with a characteristic clinical subgroup, and therefore help in establishing the correct diagnosis, classifying the myositis patients in a homogeneous subset, and facilitating the clinical and treatment follow-up. Autoantibodies to six of the aminoacyl tRNA synthetases are each associated with a similar syndrome marked by myositis, interstitial lung disease, arthritis, and other features constituting an “antisynthetase syndrome.” Antibodies to other cytoplasmic antigens that are involved in protein synthesis or translation factors are seen in a small proportion of patients. Antisignal recognition particles are associated with severe, refractory myositis that differs significantly from antisynthetase syndrome. Antibodies to the nuclear antigen are specifically seen in patietnts with DM. Several autoantibodies, including anti-U1 RNP, anti-U2 RNP, anti-Ku, and anti-PM-Scl, have been associated with scleroderma–PM overlap. In recent years, these MSAs and their antigens have been characterized using molecular biology approaches. It is not known if the MSAs are involved in tissue injury or the pathogenesis of PM/DM. However, an understanding of the production mechanisms of these autoantibodies can provide insight into the etiology of this disorder.",
keywords = "Anti-SRP antibodies, Antiaminoacyl-tRNA synthetase, Interstitial lung disease, Myositis-specific autoantibodies, Polymyositis/dermatomyositis",
author = "Michito Hirakata",
year = "2000",
month = "1",
day = "12",
doi = "10.3109/s101650070002",
language = "English",
volume = "10",
pages = "199--206",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Humoral aspects of polymyositis/dermatomyositis

AU - Hirakata, Michito

PY - 2000/1/12

Y1 - 2000/1/12

N2 - Evidence of the involvement of systemic autoimmunity has been observed in polymyositis/dermatomyositis (PM/DM). Autoantibodies directed against various cellular constituents have been detected in most patients with PM/DM, and about one-third of patients have autoantibodies (myositis-specific antibodies: MSAs) that are found specifically in myositis patients. These autoantibodies are closely associated with a characteristic clinical subgroup, and therefore help in establishing the correct diagnosis, classifying the myositis patients in a homogeneous subset, and facilitating the clinical and treatment follow-up. Autoantibodies to six of the aminoacyl tRNA synthetases are each associated with a similar syndrome marked by myositis, interstitial lung disease, arthritis, and other features constituting an “antisynthetase syndrome.” Antibodies to other cytoplasmic antigens that are involved in protein synthesis or translation factors are seen in a small proportion of patients. Antisignal recognition particles are associated with severe, refractory myositis that differs significantly from antisynthetase syndrome. Antibodies to the nuclear antigen are specifically seen in patietnts with DM. Several autoantibodies, including anti-U1 RNP, anti-U2 RNP, anti-Ku, and anti-PM-Scl, have been associated with scleroderma–PM overlap. In recent years, these MSAs and their antigens have been characterized using molecular biology approaches. It is not known if the MSAs are involved in tissue injury or the pathogenesis of PM/DM. However, an understanding of the production mechanisms of these autoantibodies can provide insight into the etiology of this disorder.

AB - Evidence of the involvement of systemic autoimmunity has been observed in polymyositis/dermatomyositis (PM/DM). Autoantibodies directed against various cellular constituents have been detected in most patients with PM/DM, and about one-third of patients have autoantibodies (myositis-specific antibodies: MSAs) that are found specifically in myositis patients. These autoantibodies are closely associated with a characteristic clinical subgroup, and therefore help in establishing the correct diagnosis, classifying the myositis patients in a homogeneous subset, and facilitating the clinical and treatment follow-up. Autoantibodies to six of the aminoacyl tRNA synthetases are each associated with a similar syndrome marked by myositis, interstitial lung disease, arthritis, and other features constituting an “antisynthetase syndrome.” Antibodies to other cytoplasmic antigens that are involved in protein synthesis or translation factors are seen in a small proportion of patients. Antisignal recognition particles are associated with severe, refractory myositis that differs significantly from antisynthetase syndrome. Antibodies to the nuclear antigen are specifically seen in patietnts with DM. Several autoantibodies, including anti-U1 RNP, anti-U2 RNP, anti-Ku, and anti-PM-Scl, have been associated with scleroderma–PM overlap. In recent years, these MSAs and their antigens have been characterized using molecular biology approaches. It is not known if the MSAs are involved in tissue injury or the pathogenesis of PM/DM. However, an understanding of the production mechanisms of these autoantibodies can provide insight into the etiology of this disorder.

KW - Anti-SRP antibodies

KW - Antiaminoacyl-tRNA synthetase

KW - Interstitial lung disease

KW - Myositis-specific autoantibodies

KW - Polymyositis/dermatomyositis

UR - http://www.scopus.com/inward/record.url?scp=85011712602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011712602&partnerID=8YFLogxK

U2 - 10.3109/s101650070002

DO - 10.3109/s101650070002

M3 - Review article

VL - 10

SP - 199

EP - 206

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 4

ER -